SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review.
- Author:
Li BAO
1
;
Xiao-Jun HUANG
Author Information
1. Institute of Hematology, People Hospital, Peking University, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Chemokine CXCL12;
metabolism;
physiology;
Humans;
Multiple Myeloma;
complications;
metabolism;
Osteolysis;
etiology;
Receptors, CXCR4;
metabolism;
physiology
- From:
Journal of Experimental Hematology
2008;16(2):442-446
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce bone destruction. Osteolytic bone lesions in MM patients mainly result from an increased bone resorption related to the stimulation of osteoclast recruitment and activity. SDF-1a would represent a potential role and may provide a suitable therapeutic target for MM-mediated osteolysis. In this article the structure of SDF-1/CXCR4, the expression of SDF-1/CXCR4 in bone microenvironment of MM patients and its effect on osteoclasts, relation of SDF-1/CXCR expression with osteolytic bone lesions and prognosis of MM, SDF-1/CXCR4 as potential target for treatment of myeloma-osteopathia were reviewed.